ArticleBlood advances2019
Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition.
Abstract read
In one paragraph
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed.
- GutBlood neoplasia · 2025Trial
- Article
- The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation.American journal of hematology · 2026Review
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- Fiber intake associates with increased treatment response in patients with multiple myeloma along with changes in gut microbiome.Blood advances · 2026Article
- Diagnosis, risk stratification and management of smouldering multiple myeloma.Nature reviews. Clinical oncology · 2026Review
- Oxidative Stress in Multiple Myeloma: Pathogenic Mechanisms, Biomarkers, and Redox-Targeted Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.Journal for immunotherapy of cancer · 2026Article
- Multi-kingdom gut microbiota analysis identifies bacterial-viral association in multiple myeloma.Frontiers in microbiology · 2026Article
- Microbiota-derived metabolites in hematopoietic regulation and disease: mechanisms, context, and therapeutic perspectives.Frontiers in microbiology · 2026Review
- Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma.Nature communications · 2025Article
- The Gut Microbiome Role in Multiple Myeloma: Emerging Insights and Therapeutic Opportunities.Hematology reports · 2025Review
- Associations Between the Gut Microbiome and Outcomes in Autologous Stem Cell Transplantation: A Systematic Review.Microorganisms · 2025Review
- Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma.Blood cancer discovery · 2025Article
- Microbiota-derived urolithin A in monoclonal gammopathies and multiple myeloma therapy.Microbiome · 2025Article
- The Positive Effects of Training and Time-Restricted Eating in Gut Microbiota Biodiversity in Patients with Multiple Myeloma.Nutrients · 2024Article
- Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future.Seminars in hematology · 2024Review
- A role for diet and gut microbiota metabolites in autologous hematopoietic cell transplant recipients.Blood cell therapy · 2024Article
- Increased abundance ofOncology letters · 2024Article
- Gut microbiota plays pivotal roles in benign and malignant hematopoiesis.Blood science (Baltimore, Md.) · 2024Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Matthew J PiankoDivision of Hematology/Oncology, Department of Internal Medicine, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI.ORCID 0000-0001-9295-9750
Sean M DevlinDepartment of Biostatistics and Epidemiology.
Eric R LittmannLucille Castori Center for Microbes, Inflammation, and Cancer.
Aisara ChansakulMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Donna MasteyMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Meghan SalcedoMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Emily FontanaLucille Castori Center for Microbes, Inflammation, and Cancer.ORCID 0000-0002-9060-5382
Lilan LingLucille Castori Center for Microbes, Inflammation, and Cancer.
Elizabet TavitianMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
John B SlingerlandSloan Kettering Institute, and.
Ann E SlingerlandSloan Kettering Institute, and.
Annelie ClurmanSloan Kettering Institute, and.
Antonio L C GomesSloan Kettering Institute, and.ORCID 0000-0003-3790-3724
Ying TaurLucille Castori Center for Microbes, Inflammation, and Cancer.ORCID 0000-0002-6601-8284
Eric G PamerLucille Castori Center for Microbes, Inflammation, and Cancer.ORCID 0000-0002-6755-9904
Jonathan U PeledWeill Cornell Medical Center, New York, NY; and.ORCID 0000-0002-4029-7625
Marcel R M van den BrinkWeill Cornell Medical Center, New York, NY; and.ORCID 0000-0003-0696-4401
Ola LandgrenMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-6485-4839
Alexander M LesokhinMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-9321-702X
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MT LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI PAMER, ERIC G. · 1985 to 2023
$59.0MClinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0MThymic and Peripheral Aspects of T Cell Aging and RejuvenationP01AG052359 · NIA · UNIVERSITY OF ARIZONA · PI Jarrod Dudakov · 2017 to 2026
$23.5MSystems Biology of Microbiome-mediated Resilience to Antibiotic-resistant PathogensU01AI124275 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI PAMER, ERIC G., XAVIER, JOAO · 2016 to 2020
$8.9MTNF Mediated Immune Defense Against Listeria InfectionR01AI042135 · NIAID · YALE UNIVERSITY · PI PAMER, ERIC G. · 1998 to 2019
$7.3MThe role of intestinal microbiota in graft-versus-host diseaseR01CA228308 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Philip L Lorenzi, Marcel R M van den Brink · 2018 to 2026
$5.2MInnate Immune Defense against Clostridium Difficile InfectionR01AI095706 · NIAID · UNIVERSITY OF CHICAGO · PI PAMER, ERIC G. · 2012 to 2020
$3.4MThe role of intestinal microbiota in graft-versus-host diseaseR01CA228358 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VAN DEN BRINK, MARCEL R M · 2018 to 2022
$2.6MMicrobiota mechanisms and biomarkers in GVHDK08HL143189 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI PELED, JONATHAN · 2019 to 2023
$858kMSKCC Clinical Research Methodology CurriculumK30RR022277 · NCRR · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI BAJORIN, DEAN F. · 2005 to 2007
$649kNCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR002384NCI NIH HHS L30 CA220724NCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA228308NCI NIH HHS R01 CA228358NCRR NIH HHS K30 RR022277NHLBI NIH HHS K08 HL143189NIAID NIH HHS R01 AI042135NIAID NIH HHS R01 AI095706NIAID NIH HHS U01 AI124275NIA NIH HHS P01 AG052359
Abstract
Patients with multiple myeloma (MM) who achieve minimal residual disease (MRD) negativity after upfront treatment have superior outcomes compared with those who remain MRD
Indexed as
Gastrointestinal MicrobiomeAdultAgedAged, 80 and overBiopsyBone MarrowCombined Modality TherapyFemaleHumansMaleMiddle AgedMultiple MyelomaNeoplasm, ResidualNeoplasm StagingTreatment Outcome
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.